Neosaxitoxin combination formulations for prolonged local anesthesia

• US 8,975,281 B2
• Filed: 07/15/2014
• Issued: 03/10/2015
• Est. Priority Date: 03/15/2013
• Status: Active Grant

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Berde, Charles, Kohane, Daniel S.
• Primary Examiner(s): Lundgren, Jeffrey S
• Assistant Examiner(s): LEE, WILLIAM Y
• Application Number:
  US14/331,983
• Publication Number:
  US 20140329861A1
• Time in Patent Office: 238 Days
• Field of Search: None
• US Class Current: 514/330
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/245 Amino benzoic acid types, e.g. procaine, novocaine salicylic acid esters A61K31/60
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations.

Claims

1. A method of use comprising administering an effective amount of a dosage unit for treatment or prevention of pain in an awake, sedated or anesthetized human child comprising an effective amount of neosaxitoxin, a local anesthetic selected from the group consisting of bupivacaine, levobupivacaine, tetracaine, and ropivacaine in a concentration range between 0.1% (1 mg/ml) and 0.5% (5 mg/ml), and epinephrine in a concentration range between 2 mcg/ml (1:

500,000) and 10 mcg/ml (1;

100,000), to produce a minimum effective concentration at the site of administration to a human child in need thereof to treat or prevent pain or provide local anesthesia.

2. The method of claim 1 wherein the human is awake.

3. The method of claim 1 comprising administrating a high volume of a formulation of between 0.5 and 1.8 ml/kg for children, comprising

Bupivacaine in a concentration range between 0.1% (1 mg/ml) and 0.25% (2.5 mg/ml), giving a total systemic bupivacaine dose of no more than 2.5 mg/kg;

NeoSTX in a concentration range from 0.1 mcg/ml-1 mcg/ml, giving a total systemic dose of 0.05-1.5 mcg/kg, and

Epinephrine in a concentration range between 2 mcg/ml (1;

500,000) and 10 mcg/ml (1;

100,000).

4. The method of claim 3 comprising administering an effective amount by infiltration of multiple layers of a large surgical wound for a full-length open laparotomy, thoraco-abdominal incision, or flank incision in a child in need thereof.

5. The method of claim 3 comprising administering an effective amount for esophago-gastrectomy, nephrectomy, or large abdominal cancer surgeries in a child in need thereof.

6. The method of claim 3 comprising administering an effective amount for wound infiltration for total hip replacement or total knee replacement in a child in need thereof.

7. The method of claim 1 for medium volume use of 15 to 50 ml comprising providing a formulation containing

Bupivacaine in a concentration range of 0.125%-0.3% (1.25-3 mg/ml), giving a systemic dose of no more than 2 mg/kg in children,

NeOSTX in a concentration range from 0.2-2 mcg/ml, giving a systemic dose of 0.1-1.5 mcg/kg in children, and

Epinephrine in a concentration range from 0-10 mcg/ml (<

1;

100,000).

8. The method of claim 7 comprising administering an effective amount for peripheral nerve blocks or plexus blocks.

9. The method of claim 7 comprising administering an effective amount for infiltration.

10. The method of claim 7 comprising administering an effective amount for shoulder, hand or arm surgery, infiltration or ilio-inguinal/ilio-hypogastric blocks for inguinal hernia repair, penile block for hypospadias repair, femoral block for total knee replacement or anterior cruciate ligament repair, intercostal nerve blocks for open chest surgery, or femoral and sciatic nerve blocks for leg amputation or foot and ankle surgery.

11. The method of claim 10 comprising performing a femoral nerve block, lumbar plexus block or lower volume sciatic block.

12. The method of claim 7 comprising administering the formulation to provide anesthesia for surgery for periods of between 3 and 12 hours, analgesia after surgery for at least 24 hours, and recovery from motor block to permit some strength in limb movement within 24 to 48 hours after administration.